March 2025 - Monthly Gold Strategy
Exclusively for Our Gold Subscribers: Explore March 2025's Expert Trading Strategy
Articles & Trading Insights
📈 Dive into expert insights on Long Shorts, Pairs Trading, and Relative Value Strategies. Grow your trading skills with clear, practical articles.
VALE vs. BHP: A Strategic Long-Short Play on Iron Ore & Valuation Gaps
We are initiating a long position in Vale S.A. (NYSE: VALE) and a short position in BHP Group Ltd. (NYSE: BHP) to capitalize on valuation inefficiencies and structural advantages. With VALE trading at a deep discount and benefiting from high-grade iron ore and currency tailwinds, while BHP faces cost pressures and weaker commodity mix, this pairs trade presents an asymmetric opportunity in the global mining sector.
February 2025 - Monthly Gold Strategy
Exclusively for Our Gold Subscribers: Explore February 2025's Expert Trading Strategy
Strategy with Chipotle (CMG) and Texas Roadhouse (TXRH)
Discover a defensive Long/Short equity strategy focusing on the restaurant sector during volatile times. This analysis contrasts Chipotle Mexican Grill's scalable, high-growth business model against Texas Roadhouse's margin challenges and slower growth, offering a hedged relative value play within the industry.
January 2025 - Monthly Gold Strategy
Exclusively for Our Gold Subscribers: Explore January 2025's Expert Trading Strategy
December 2024 - Monthly Gold Strategy
Exclusively for Our Gold Subscribers: Explore December 2024's Expert Trading Strategy
Enphase Energy vs. Woodside Energy: A Long-Short Strategy for Diverging Energy Markets
Discover a long-short strategy capitalizing on renewable energy growth with Enphase (ENPH) and fossil fuel risks with Woodside (WDS). Explore valuation gaps, market trends, and an opportunity for balanced returns.
November 2024 - Monthly Gold Strategy
Exclusively for Our Gold Subscribers: Explore November 2024's Expert Trading Strategy
Unlocking the Biotech Sector: A Strategic Long-Short Investment Opportunity
Explore a biotech long-short strategy: AbbVie’s strong cash flows and M&A vs. Vertex’s concentrated CF risk. Leverage market volatility and mean reversion for balanced gains and reduced portfolio risks.